10 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 17 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 10, Terminated 3, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Endometrial Clear Cell Adenocarcinoma: new trials by email Literature Review of Endometrial Clear Cell Adenocarcinoma trials Research Report on Endometrial Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Biospecimen Collection, Computed Tomography, Ipilimumab - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 81 | 2022-06-02 | 2026-11-04 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Mirvetuximab Soravtansine, Bevacizumab - Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | Withdrawn | University of Oklahoma | 2019-05-31 | 2019-06-27 | |
| Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Metformin Hydrochloride, Doxycycline - Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2016-06-08 | 2026-04-22 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 / Phase 3 | Unknown | Gynecologic Oncology Group | 469 | 2014-03-17 | 2021-09-30 |
| Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Dasatinib, Laboratory Biomarker Analysis - Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 35 | 2014-02-14 | 2023-08-01 |
| Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 102 | 2013-05-08 | 2025-10-01 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Dalantercept, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 28 | 2012-09-01 | 2018-03-13 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Nintedanib - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 37 | 2011-10-01 | 2017-10-09 |
| Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Trebananib - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 35 | 2011-06-06 | 2018-02-23 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2011-03-01 | 2022-02-11 |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Cediranib Maleate, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 53 | 2010-06-01 | 2019-08-08 |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Bevacizumab, Carboplatin, Cisplatin - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2009-11-06 | 2018-03-15 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Bevacizumab, Carboplatin, Ixabepilone - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 349 | 2009-09-14 | 2026-09-09 |
| Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Diagnostic Laboratory Biomarker Analysis, Selumetinib - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 54 | 2009-09-01 | 2019-07-23 |
| Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Brivanib Alaninate, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 45 | 2009-07-06 | 2017-12-06 |
| Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Gemcitabine Hydrochloride - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 24 | 2009-02-01 | 2017-12-29 |
Carcinoma, Endometrioid (3) · Endometrial Neoplasms (3) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Krukenberg Tumor (1) · Ovarian Diseases (1) · Recurrence (1) · Sarcoma, Endometrial Stromal (1) · Uterine Diseases (1)
Neoplasms (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Neoplasms by Site (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Uterine Neoplasms (5) · Adnexal Diseases (4) · Endocrine System Diseases (4) · Gonadal Disorders (4) · Neoplasms by Histologic Type (4) · Adenocarcinoma (3)
Bevacizumab (3) · Carboplatin (3) · Paclitaxel (3) · Taxes (3) · Disulfides (2) · Immunoglobulin G (2) · Metformin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · ALK1-Fc fusion protein, human (1) · AZD 6244 (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Dasatinib (1) · Doxycycline (1) · Epothilones (1)
National Cancer Institute (NCI) (8) · Gynecologic Oncology Group (6) · Elucida Oncology (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Oklahoma (1)
United States (17) · Canada (2) · Hong Kong (1)
Akila Viswanathan (1) · Carol Aghajanian (1) · David Bender (1) · David M Hyman (1) · David Tait (1) · Don Dizon (1) · Haider S Mahdi (1) · Jennifer Johnson, MD, PhD (1) · Kathleen Moore (1) · Matthew Powell (1) · Neesha Dhani (1) · Panagiotis Konstantinopoulos (1) · Robert Coleman (1) · Vicky Makker (1) · Victoria L Bae-Jump (1)
PMID 25312396, PMID 25847373, PMID 25887099, PMID 31714586, PMID 31992589, PMID 33541735, PMID 35658479
U10CA027469 (10), U10CA180868 (10), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), P30CA006516 (1), U01CA062490 (1), U10CA021661 (1), U10CA180830 (1), UM1CA186644 (1), UM1CA186709 (1)